Autoimmune rheumatic diseases and their association with killer immunoglobulin-like receptor genes

Revista Brasileira de Reumatologia

Volumn 51, Issue 4, 2011, Pages 351-364

  Salim, Patricia Hartstein ^a   Jobim, Mariana ^a,b   Jobim, Luiz Fernando ^a,c   Xavier, Ricardo Machado ^a,d  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c HCPA/UFRGS ^*  (Brazil)

^d SHIMANE UNIVERSITY   (Japan)

Author keywords

Autoimmunity; KIR receptors; Systemic sclerosis

Indexed keywords

HLA ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL4; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL5; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DS1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DS2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DS5; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DS1; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL ACTIVATION; CELL MEMBRANE; CHROMOSOME 19Q; CYTOLYSIS; GENE; GENE EXPRESSION; GENE STRUCTURE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; IMMUNOSURVEILLANCE; INHIBITION KINETICS; INNATE IMMUNITY; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR GENE; NATURAL KILLER CELL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TARGET CELL;

AUTOIMMUNE DISEASES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KILLER CELLS, NATURAL; RECEPTORS, KIR; RHEUMATIC DISEASES;

EID: 79960595589     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Jobim M, Jobim LF. Natural killer cells and immune surveillance. J Pediatr (Rio J) 2008; 84(4 Suppl):S58-65.
2. Yu J, Venstrom JM, Liu XR, O'Reilly R, Pring J, Hasan RS et al. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function following T-cell depleted allogeneic hematopoietic cell transplantation. Blood 2009; 113(16):3875-84.
3. Freud AG, Caligiuri MA. Human natural killer cell development. Immunol Rev 2006; 214:56-61.
4. Di Santo JP, Vosshenrich CA. Bone marrow versus thymic pathways of natural killer cell development. Immunol Rev 2006; 214:35-9.
5. Cooper MA, Elliott JM, Keyel PA, Yang L, Carrero JA, Yokoyama WM. Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci USA 2009; 106(6):1915-21.
6. Farag SS, VanDeusen JB, Fehniger TA, Caligiuri MA. Biology and clinical impact of human natural killer cells. Int J Hematol 2003; 78(1):7-13.
7. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56 (bright) subset. Blood 2001; 97(10):3146-51.
8. Keskin DB, Allan DS, Rybalov B, Andzelm MM, Stern JN, Kopcow HD et al. TGF-beta promotes conversion of CD16+ peripheral blood NK cells into CD16- NK cells with similarities to decidual NK cells. Proc Natl Acad Sci USA 2007; 104(9):3378-84.
9. Jacobs R, Hintzen G, Kemper A, Beul K, Kempf S, Behrens G et al. CD56 bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur J Immunol 2001; 31(10):3121-27.
10. Schepis D, Gunnarsson I, Eloranta ML, Lampa J, Jacobson SH, Karre K et al. Increased proportion of CD56 bright natural killer cells in active and inactive systemic lupus erythematosus. Immunology 2009; 126(1):140-7.
11. Takahashi E, Kuranaga N, Satoh K, Habu Y, Shinomiya N, Asano T et al. Induction of CD16+ CD56 bright NK cells with antitumour cytotoxicity not only from CD16- CD56 bright NK Cells but also from CD16- CD56 dim NK cells. Scand J Immunol 2007; 65(2):126-9.
12. Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M et al. CD56 bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003; 101(8):3052-7.
13. Zhang AL, Colmenero P, Purath U, Matos CT, Hueber W, Klareskog L et al. Natural killer cells trigger differentiation of monocytes into dendritic cells. Blood 2007; 110(7):2484-9.
14. Trapani JA, Smyth MJ. Functional signifcance of the perforin/ granzyme cell death pathway. Nat Rev Immunol 2002; 2(10):735-9.
15. Arase H, Arase N, Saito T. Fas-mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med 1995; 181(3):1235-8.
16. Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature 2009; 457(7229):557-62.
17. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 1285 (5428):727-33.
18. Bottino C, Vitale M, Pende D, Biassoni R, Moretta A. Receptors for HLA class I molecules in human NK cells. Semin Immunol 1995; 7(2):67-73.
19. Moretta L, Bottino C, Pende D, Vitale M, Mingari MC, Moretta A. Different checkpoints in human NK-cell activation. Trends Immunol 2004; 25(12):670-8.
20. Boyton RJ, Altmann DM. Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease. Clin Exp Immunol 2007; 149(1):1-6.
21. Moretta A, Tambussi G, Bottino C, Tripodi G, Merli A, Ciccone E et al. A novel surface antigen expressed by a subset of human CD3-CD16+ natural killer cells. Role in cell activation and regulation of cytolytic function. J Exp Med 1990; 171(3):695-9.
22. van Kaer L. NKT cells: T lymphocytes with innate effector functions. Curr Opin Immunol 2007; 19(3):354-8.
23. Suto Y, Maenaka K, Yabe T, Hirai M, Tokunaga K, Tadok K et al. Chromosomal localization of the human natural killer cell class I receptor family genes to 19q13.4 by fuorescence in situ hybridization. Genomics 1996; 35(1):270-7.
24. Martin AM, Freitas EM, Witt CS, Christiansen FT. The genomic organization and evolution of the natural killer immunoglobulin-like receptor (KIR) gene cluster. Immunogenetics 2000; 51(4-5):268-74.
25. Wilson MJ, Torkar M, Haude A, Milne S, Jones T, Sheer D et al. Plasticity in the organization and sequences of human KIR/ILT gene families. Proc Natl Acad Sci USA 2000; 97(9):4778-85.
26. Moretta A, Sivori S, Vitale M, Pende D, Morelli L, Augugliaro R et al. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med 1995; 182(3):875-9.
27. Fan QR, Mosyak L, Winter CC, Wagtmann N, Long EO, Wiley DC. Structure of the inhibitory receptor for human natural killer cells resembles haematopoietic receptors. Nature 1997; 389(6646):96-104.
28. Biassoni R, Cantoni C, Falco M, Verdiani S, Bottino C, Vitale M et al. The human leukocyte antigen (HLA)-C-specifc "activatory" or "inhibitory" natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions. J Exp Med 1996; 183(2):645-52.
29. Marsh SG, Parham P, Dupont B, Geraghty DE, Trowsdale J, Middleton D et al. Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002. Eur J Immunogenet 2003; 30(3):229-33.
30. Wagtmann N, Biassoni R, Cantoni C, Verdiani S, Malnati SMS, Vitale M et al. Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra-and intracellular domains. Immunity 1995; 2(5):439-45.
31. Parham. Immunogenetics of killer cell immunoglobulin-like receptors. Mol Immunol 2005; 42(4):459-64.
32. Wende H, Colonna M, Ziegler A, Volz A. Organization of the leukocyte receptor cluster (LRC) on human chromosome 19q13.4. Mamm Genome 1999; 10(2):154-9.
33. Middleton D, Meenagh A, Moscoso J, Arnaiz-Villena A. Killer immunoglobulin receptor gene and allele frequencies in Caucasoid, Oriental and Black populations from different continents. Tissue Antigens 2008; 71(2):105-9.
34. Martin MR, Single RM, Wilson MJ, Trowsdale J, Carrington M. KIR haplotypes defned by segregation analysis in 59 Centre dEtude Polymorphisme Humain (CEPH) families. Immunogenetics 2008; 60(12):767-72.
35. Momot T, Koch S, Hunzelmann N, Krieg T, Ulbricht K, Schmidt RE et al. Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum. 2004; 50(5):1561-5.
36. Pellett F, Siannis F, Vukin I, Lee P, Urowitz MB, Gladman DD. KIRs and autoimmune disease: studies in systemic lupus erythematosus and scleroderma. Tissue Antigens 2007; 69(Suppl 1):106-8
37. Kimoto Y, Horiuchi T, Tsukamoto H, Kiyohara C, Mitoma H, Uchino A et al. Association of killer cell immunoglobulin-like receptor 2DL5 with systemic lupus erythematosus and accompanying infections. Rheumatology (Oxford). 2010; 49(7):1346-53.
38. Hou YF, Zhang YC, Jiao YL, Wang LC, Li JF, Pan ZL et al. Disparate distribution of activating and inhibitory killer cell immunoglobulin-like receptor genes in patients with systemic lupus erythematosus. Lupus. 2010; 19(1):20-6.
39. Pedroza L, Sauma M, Vasconcelos JM, Takeshita LY, Ribeiro-Rodrigues EM, Sastre D et al. Systemic Lupus Erythematosus: Association with KIR and SLC11A1 polymorphisms, ethnic predisposition and infuence in clinical manifestations at onset revealed by ancestry genetic markers in an urban Brazilian population. Lupus. 2011; 20(3):265-73.
40. Jiao YL, Ma CY, Wang LC, Cui B, Zhang J, You L et al. Polymorphisms of KIRs gene and HLA-C alleles in patients with ankylosing spondylitis: possible association with susceptibility to the disease. J Clin Immunol. 2008; 28(4):343-9.
41. Lopez-Larrea C, Blanco-Gelaz MA, Torre-Alonso JC, Bruges Armas J, Suarez-Alvarez B, Pruneda L et al. Contribution of KIR3DL1/3DS1 to ankylosing spondylitis in human leukocyte antigen-B27 Caucasian populations. Arthritis Res Ther. 2006; 8(4):R101-4.
42. Díaz-Peña R, Blanco-Gelaz MA, Suárez-Alvarez B, Martínez-Borra J, López-Vázquez A, Alonso-Arias R et al. Activating KIR genes are associated with ankylosing spondylitis in Asian populations. Hum Immunol. 2008; 69(7):437-42.
43. Jiao YL, Zhang BC, You L, Li JF, Zhang J, Ma CY et al. Polymorphisms of KIR gene and HLA-C alleles: possible association with susceptibility to HLA-B27-positive patients with ankylosing spondylitis. J Clin Immunol. 2010; 30(6):840-4.
44. Harvey D, Pointon JJ, Sleator C, Meenagh A, Farrar C, Sun JY et al. Analysis of killer immunoglobulin-like receptor genes in ankylosing spondylitis. Ann Rheum Dis. 2009; 68(4):595-8.
45. Díaz-Peña R, Vidal-Castiñeira JR, Alonso-Arias R, Suarez-Alvarez B, Vicario JL, Solana R et al. Association of the KIR3DS1*013 and KIR3DL1*004 alleles with susceptibility to ankylosing spondylitis. Arthritis Rheum. 2010; 62(4):1000-6.
46. Mousavi T, Poormoghim H, Moradi M, Tajik N, Shahsavar F, Asadifar B. Inhibitory killer cell immunoglobulin-like receptor KIR3DL1 in combination with HLA-B Bw4iso protect against ankylosing spondylitis. Iran J Immunol. 2010; 7(2):88-95.
47. Majorczyk E, Pawlik A, Łuszczek W, Nowak I, Wiśniewski A, Jasek M et al. Associations of killer cell immunoglobulin-like receptor genes with complications of rheumatoid arthritis. Genes Immun. 2007; 8(8):678-83.
48. Kogure T, Tatsumi T, Niizawa A, Fujinaga H, Ito T, Shimada Y et al. No correlation exists between disease activity and the expression of killer-cell immunoglobulin-like receptors in patients with rheumatoid arthritis. Mediators Infamm. 2007; 2007:65179-83.